One taker in four years, but MHRA/NICE persist on parallel advice
This article was originally published in Scrip
Executive Summary
Regulators and health technology assessors in the UK are trying to breathe life into a program that is aimed at providing drug companies with parallel scientific advice on their product development plans but which has only been used once in the more than four years it has been available.